Cargando…
PHASE 2 RANDOMIZED STUDY (ORION-1) OF A NOVEL, BIODEGRADABLE DEXAMETHASONE IMPLANT (AR-1105) FOR THE TREATMENT OF MACULAR EDEMA DUE TO CENTRAL OR BRANCH RETINAL VEIN OCCLUSION
AR-1105 is a novel biodegradable sustained-release dexamethasone implant designed to deliver 6-month durability. This Phase 2 study evaluated two AR-1105 formulations with different release profiles in patients with macular edema due to retinal vein occlusion. METHODS: Patients received a single int...
Autores principales: | Singer, Michael A., Boyer, David S., Williams, Stuart, McKee, Hayley, Kerr, Kevin, Pegoraro, Tyler, Trevino, Leo, Kopczynski, Casey C., Hollander, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Retina
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750099/ https://www.ncbi.nlm.nih.gov/pubmed/36542081 http://dx.doi.org/10.1097/IAE.0000000000003632 |
Ejemplares similares
-
Orion
por: Glass, Philip, et al.
Publicado: (2005) -
Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11
por: Koenig, Wolfgang, et al.
Publicado: (2023) -
Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)
por: Nakamura, Nobuhiko, et al.
Publicado: (2021) -
HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)
por: Ri, Masaki, et al.
Publicado: (2021) -
ORION: An Advanced Accelerator Facility at SLAC
por: Palmer, D T, et al.
Publicado: (2001)